Journal article

Loss of STARD 10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status

Niamh C Murphy, Andrew V Biankin, Ewan KA Millar, Catriona M McNeil, Sandra A O'Toole, Davendra Segara, Paul Crea, Monilola A Olayioye, C Soon Lee, Stephen B Fox, Adrienne L Morey, Michael Christie, Elizabeth A Musgrove, Roger J Daly, Geoffrey J Lindeman, Susan M Henshall, Jane E Visvader, Robert L Sutherland



The phospholipid transfer protein STARD10 cooperates with c-erbB signaling and is overexpressed in Neu/ErbB2 breast cancers. We investigated if STARD10 expression provides additional prognostic information to HER2/neu status in primary breast cancer. A published gene expression dataset was used to determine relationships between STARD10 and HER2 mRNA levels and patient outcome. The central findings were independently validated by immunohistochemistry in a retrospective cohort of 222 patients with breast cancer with a median follow-up of 64 months. Kaplan-Meier and Cox proportional hazards analyses were used for univariate and multivariate analyses. Patients with low STARD10 or high HER2 tumo..

View full abstract